# Feasibility Assessment: Surviving TDP-43 → mPTP Upstream Mechanisms
**Scope:** Five hypotheses proposed; Skeptic analysis reduced confidences. Hypotheses with revised confidence ≥ 0.50 are assessed below. Hypothesis 3 (VDAC1 hyper-oligomerization, confidence 0.38) is excluded on the basis of membrane compartment mismatch and physical incoherence—it cannot explain IMM-localized mPTP-dependent mtDNA release.
---
## Hypotheses Retained for Assessment
| # | Title | Original | Revised | Retained |
|---|-------|----------|---------|----------|
| 1 | CypD Displacement | 0.72 | 0.52 | ✓ |
| 2 | TOM/TIM Disruption → mtISR | 0.65 | 0.58 | ✓ |
| 4 | MCU Ca²⁺ Overload via MAM Dysfunction | 0.68 | ~0.55* | ✓ |
| 5 | Drp1 Fission Priming | 0.68 | Incomplete | ✓ |
*Skeptic's critique of MCU was partially truncated but raised valid issues around cascade complexity and specificity; provisional revision to 0.55.
---
## Hypothesis 1: CypD Displacement
### Druggability
**High, but undermined by clinical precedent.** CypD (PPID) is one of the most extensively drugged mitochondrial proteins. Cyclosporine A, sangliferin A, and the novel inhibitor JW-35 bind the CypD isomerase pocket with nanomolar affinity. The human trial failure (NCT00740769) is the critical confounder: if CypD displacement is the upstream mechanism, a CypD inhibitor should have attenuated mtDNA release and reduced neuroinflammation in ALS—yet it did not. **This is a fundamental therapeutic disconfirmation.** Reformulation of CypD inhibitors for CNS delivery has been attempted (Debio-025/alisporivir), but the target validation problem persists—CypD-mediated mPTP may be downstream but not the dominant driver in human disease.
- **Existing tool compounds:** Cyclosporine A, sangliferin A, NIM811 (non-immunosuppressive analog)
- **Liability:** Immunosuppression (CsA), narrow therapeutic index, CYP3A4 interaction
- **Blood-brain barrier penetration:** Poor for CsA; NIM811 somewhat better but still limited
### Biomarkers
- **Fluid:** Plasma mtDNA copy number (emerging as proxy for mitochondrial permeability); CSF neurofilament light chain (NfL) as downstream neurodegeneration marker
- **Imaging:** No validated PET ligand for CypD or mPTP status
- **Translational gap:** None of these directly confirm CypD displacement in situ; they reflect downstream mtDNA release or neuronal injury
### Model Systems
- **Strength:** CypD knockout mice are viable and show mPTP resistance; iPSC-derived motor neurons from ALS patients allow co-IP assessment of TDP-43:CypD proximity
- **Critical limitation:** Human CypD inhibitors failed in ALS, suggesting species differences or disease-stage specificity not captured in rodent models
- **Recommended system:** iPSC motor neurons with matrix-targeted TDP-43 expression (Skeptic's falsifying experiment) combined with CypD CRISPR knockout to dissect pathway
### Clinical Development Constraints
- **Primary constraint:** Prior phase II failure (NCT00740769) will create regulatory and investor skepticism; the failure may reflect timing (intervention after symptom onset) rather than mechanism, but this distinction must be explicitly addressed
- **Regulatory pathway:** Would require re-profiling as neuroinflammatory disease modifier with mtDNA/cGAS-STING biomarkers as pharmacodynamic endpoints
- **Indication scope:** ALS, ALS-FTD, and potentially sALS given TDP-43 pathology is not restricted to familial forms
### Safety
- **On-target:** CypD inhibition globally reduces mPTP sensitivity—beneficial for neurons but potentially problematic for cardiac ischemia-reperfusion tolerance; the heart relies on mPTP opening in stress conditions
- **Off-target:** CsA has calcineurin inhibition liability; non-immunosuppressive CypD inhibitors mitigate this but have limited CNS penetration data
- **Mitochondrial liability:** Prolonged mPTP suppression could impair quality control mitophagy in high-turnover tissues
### Timeline and Cost
- **Accelerated path:** Existing preclinical tool compounds and regulatory familiarity with CypD as a target
- **Timeline:** IND-enabling studies could complete in 18–24 months given existing pharmacology; however, the clinical failure must be explained in the new mechanistic context (mtDNA release vs. general neuroprotection), adding 12 months of translational biomarker development
- **Estimated cost:** $15–20M to IND; $50–80M through Phase IIa (small patient population, ~100–150 subjects)
**Overall feasibility: Moderate.** High target druggability offset by prior clinical failure. The mechanistic explanation required before proceeding is precisely the upstream question this program aims to address.
---
## Hypothesis 2: TOM/TIM Complex Disruption → mtISR
### Druggability
**Moderate and mechanistically distinct from Hypothesis 1.** The outer mitochondrial membrane translocase (TOMM40/TOMM70) is a membrane-embedded protein complex with protein-protein interaction surfaces—not a classic enzyme pocket. This is a meaningful therapeutic differentiation, as it implies targeting a regulatory interaction rather than an active site.
- **Entry points:** TOMM70 has exposed cytosolic domains amenable to stapled peptide or small-molecule disruption; Hsp90 inhibitors indirectly stabilize the import machinery (17-DMAG, geldanamycin derivatives); CLPP protease activation as a complementary approach to clear import-backlogged proteins
- **Challenges:** TOM/TIM interfaces involve large, flat interaction surfaces; small molecules are unlikely to fully restore import function; stapled peptides have CNS delivery challenges
- **Novel angle:** The mtISR pathway (CLPP/ATFS-1 axis) is a transcription factor–mediated stress response—UPR^mt activators could be screened in a TDP-43 background
### Biomarkers
- **Fluid:** Matrix mitochondrial proteins mistargeted to cytosol (e.g., mitochondrial enzyme fragments in plasma); plasma N-acetylaspartate as mitochondrial metabolic marker; mtDNA as terminal readout
- **Imaging:** Mitochondrial protein import can be assessed via a luciferase-based reporter assay in patient-derived cells—an indirect but quantifiable biomarker
- **Translational gap:** The connection to CHOP is speculative (as Skeptic noted); biomarkers for the mtISR branch specifically are poorly established in human CSF/plasma
### Model Systems
- **Strength:** The 2024 proximity-labeling study (PMID:38245738) provides a direct interaction anchor; human iPSC motor neurons allow functional import assays; mitochondrial matrix proteomics is technically mature
- **Recommended system:** Isotopic pulse-chase labeling of nuclear-encoded mitochondrial proteins (e.g., [¹³C]-leucine) to quantify import kinetics before/after TDP-43 accumulation in iPSC motor neurons
### Clinical Development Constraints
- **Novel target:** No prior clinical trials on TOM/TIM modulators in neurodegeneration; target validation in human tissue is a prerequisite
- **Mechanistic specificity concern:** Protein import disruption may cause general mitochondrial dysfunction, making it difficult to isolate mPTP-specific therapeutic benefit from overall bioenergetic rescue
- **Patient stratification:** Only a subset of ALS/FTD patients with TDP-43 pathology would be eligible; no genetic polymorphism in TOM/TIM genes currently links to ALS risk, limiting predictive biomarkers for patient selection
### Safety
- **Low direct safety signal anticipated:** TOMM70 knockdown is tolerated in many cell types; the mtISR is a stress response pathway—partial activation or restoration may normalize pathology without disrupting basal function
- **Potential liability:** Overactive mtISR could itself drive apoptosis via CHOP; chronic activation of mitochondrial quality control